Pharmacoprophylaxis of liver diseases: creating a new hepatoprotector

Open Access

Table 1.

Biochemical parameters of blood plasma under the action of compound I

Indicator	Intact group	The control group (CCl4)	Experimental group 1 / Compound I + CCl4	Experimental group 2 / Mexidol + CCl4
Alanine aminotransferase, E / l protein	57.30 ± 7.62	142.30 ±9.17^*	79.10± 0.30^*	110.10 ± 0.45
Aspartate aminotransferase, E / l protein	149.20 ± 22.39	411.50 ± 24.82^*	209.30 ± 20.57^*	264.60 ± 12.03^*
Alkaline phosphatase, E / l protein	369.80 ± 39.50	438.10 ± 20.54^*	392.40 ± 20.15	403.70 ± 21.20
Bilirubin, micromol / l protein	2.70 ± 0.80	13.20 ± 0.70^*	6.60 ± 1.50^*	8.10 ± 1.90^*
DC, micromol / g protein	17.20 ± 0.55	25.36 ± 0.39^*	19.11 ± 0.37	21.13 ± 0.45
MDA, nM / mg protein	0.39 ± 0.03	0.72 ± 0.02^*	0.43 ± 0.02^*	0.44 ± 0.03^*
Catalase, M / min / mg protein	2.37 ± 0.21	1.19 ± 0.20^*	2.20 ± 0.18^*	1.87 ± 0.20^*
SOD, ng / g protein	214.50 ± 2.18	170.22 ± 2.04^*	198.36 ± 1.87^*	186.28 ± 1.94^*

Data are presented in the form: X ± Ax; n = 10, where X is the average value, Ax is the standard error of the mean, n is the number of animals in the groups. * – significant differences are indicated in comparison with the group of intact animals at p<0.05.

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.